The patent-pending system introduces a novel method for detecting superparamagnetic nanoparticles in magnetic test strips. It incorporates a magnetic field generator activated by an excitation signal, paired with a magnetic field sensor that measures shifts in magnetic field strength. When specific biomarkers are present in a sample, the sensor detects these changes, allowing for accurate detection and measurement of target analytes.

"Our technology marks a significant advancement in point-of-care diagnostics," said Marco Witteveen, CEO of Magnasense. "The enhanced sensitivity and precision of our system will enable earlier, more reliable detection of biomarkers across a wide range of conditions and sample types. This innovation has the potential to reduce cost per test and redefine how diagnostic testing is conducted."

The patent-pending system introduces a novel method for detecting superparamagnetic nanoparticles in magnetic test strips. It incorporates a magnetic field generator activated by an excitation signal, paired with a magnetic field sensor that measures shifts in magnetic field strength. When specific biomarkers are present in a sample, the sensor detects these changes, allowing for accurate detection and measurement of target analytes. The application filling number is 63/693,525.

Ideally suited for point-of-care applications, the technology facilitates rapid, dependable diagnostics without the need for complex lab infrastructure. Its versatility allows it to be applied across various disease states, providing healthcare professionals with the tools to make quicker, better-informed decisions. This breakthrough promises to have wide-reaching applications in healthcare, benefiting both medical practitioners and patients through improved diagnostic accuracy.